Filing Details

Accession Number:
0000919574-10-002182
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-03-09 12:00:00
Reporting Period:
2010-03-05
Filing Date:
2010-03-09
Accepted Time:
2010-03-09 12:00:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1124608 Response Genetics Inc RGDX In Vitro & In Vivo Diagnostic Substances (2835) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1315309 Partnership Limited Partners Lansdowne 15 Davies Street
London
W1K 3Ag X0
No No Yes No
1469444 Ltd Fund Master Investment Strategic Uk Lansdowne C/O Fortis Prime Fund Solutions
Fortis House, Park Lane, Spencer Dock
Dublin I L2
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.01 Per Share Acquisiton 2010-03-05 600,769 $1.31 3,658,676 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, Par Value $0.01 Per Share 3,658,676 Indirect See Footnote
Footnotes
  1. These reported securities are held in the account of Lansdowne UK Strategic Investment Master Fund Limited (the "Master Fund"). The Master Fund entered into apurchase agreement with the Issuer as of March 5, 2010 whereby the Master Fund acquired 600,769 shares of common stock from the Issuer in a private transaction(the "Acquisition"). The Master Fund entered into the Acquisition in order to maintain the same percentage of common stock that it beneficially owned prior to theissuance of additional shares of equity securities by the Issuer. Therefore, the percentage of shares beneficially owned by the Master Fund did not change as aresult of the Acquisition.
  2. These reported securities are held in the account of the Master Fund and may be deemed to be beneficially owned by Lansdowne Partners Limited Partnership byvirtue of its role as the investment advisor of the Fund. Lansdowne Partners Limited Partnership disclaims beneficial ownership of the reported securities except tothe extent of its pecuniary interest therein, and this report shall not be deemed an admission that Lansdowne Partners Limited Partnership is the beneficial owner ofthese securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.